Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1.

Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases.

Following a Series B fundraise, and supported by both the Scottish Investment Bank and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology.

We are currently preparing to initiate a First-in-Human clinical oncology study with our lead antibody, MDX-124, later this year. Our non-clinical therapeutic development programme for autoimmune diseases continues in parallel.

 

Medannex has been shortlisted as a finalist for both ‘Investment of the Year’ and ‘Outstanding Skills Development’ at Scotland’s Life Sciences Annual Awards 2021.


 

Medannex is a proud signatory of the Scottish Business Pledge, showing our commitment to building sustainable growth whilst maintaining fairness, equality, opportunity and innovation.

more


Meet the Team


Latest News


“Medannex has identified a novel and promising target for immunotherapy, and I am delighted to offer guidance as the company prepares for its First-in-Human study.”

Dr Stefan Symeonides,
head of Phase I Trials at the CRUK Edinburgh Centre


Collaborations & Affiliations

Medannex is proud to collaborate with leading academic researchers, play an active role within several industry associations and provide extensive skills development opportunities.